Prime Medicine Doses First Patient in Trial of Investigational Wilson Disease Treatment
MT Newswires Live
Oct 05
Prime Medicine (PRME) has dosed its first patient in a phase 1/2 clinical trial of PM577a, an investigational in vivo treatment for H1069Q-mutated Wilson disease, the company said Monday.
The study will initially enroll adults who are clinically stable and being treated with standard-of-care therapy, the company said.
Initial clinical data are expected next year, the company added.
The biotechnology company also said the US Food and Drug Administration has granted Rare Pediatric Disease designation to PM577 for Wilson disease.
Wilson disease is a rare, progressive genetic disorder which leads to copper accumulation in the liver, followed by damage to other organs, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.